 |
|
|
|
 |
|
|
| Article 1 to 10 out of 18 concerning UCB Pharma S.A.
|
-
UCB's Cimzia® filed with EMEA for treatment of rheumatoid arthritis
(07/03/2008)
The European marketing authorisation application for Cimzia® has been filed. Subject to approval, Cimzia® will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor alpha) biologic therapy.
UCB announced that a Marketing Authorisation Application (MAA) has been submitted to the European Medicines Agency (EMEA) requesting the approval of Cimzia® (certolizumab pegol) as a subcutaneous treatment for adults with moderate to severe active ...
-
UCB: Phase II results for CDP791 in non-small cell lung cancer support further clinical development
(04/01/2008)
UCB announced first results of its phase II exploratory study of CDP791, a specific VEGFR-2/KDR inhibitor, in combination with carboplatin and paclitaxel chemotherapy in first line non-small cell lung cancer (NSCLC). Positive improvements were ...
-
Changes in UCB's Executive Committee
(03/04/2008)
UCB announced the appointment of Iris Löw-Friedrich, Executive Vice President, Development and Chief Medical Officer and Fabrice Enderlin, Executive Vice President, Corporate Human Resources as new members of UCB's Executive Committee with effect ...
-
New Phase III Trial Shows Positive Outcome of lacosamide in Patients with Diabetic Neuropathic Pain
(12/13/2007)
Sustained improvements in daily pain scores demonstrated in the latest study with Vimpat (lacosamide)
UCB announced positive results from a Phase III trial evaluating lacosamide (400 mg per day) in the treatment of diabetic neuropathic pain. With a standard titration regimen, the trial met its primary objective with sustained and statistically ...
-
Neupro Filed in Europe for the Treatment of Restless Legs Syndrome
(12/07/2007)
UCB announced that the application for marketing authorization for the use of Neupro® in the treatment of moderate-to-severe Restless Legs Syndrome (RLS) has been accepted for filing by the European Medicines Agency (EMEA). Neupro® is a once-daily ...
-
UCB Announces Positive Phase III Trial Results for Keppra XR
(12/05/2007)
UCB announced results of a Phase III trial demonstrating that its antiepileptic drug (AED) in development Keppra XR(TM) (levetiracetam) extended-release tablets significantly reduced partial onset seizure frequency when administered as adjunctive ...
-
UCB's Keppra patent litigation in the US settled
(10/08/2007)
UCB announced that it has reached agreement with each of Mylan Laboratories and Mylan Pharmaceuticals, Dr. Reddy's Laboratories and Cobalt Pharmaceuticals to settle pending patent infringement lawsuits in the U.S. District Court for the Northern ...
-
Domainex and UCB successfully complete their first collaborative project
(07/20/2007)
Domainex and UCB have successfully completed their first collaborative project with the creation of a particularly elusive target protein construct. Domainex used its Combinatorial Domain Hunting technology to identify a soluble and highly-expressed ...
-
UCB selects ZoBio for Fragment Based Drug Discovery services
(07/16/2007)
ZoBio BV announced that UCB S.A. has selected ZoBio to provide ligand discovery services in the field of Fragment Based Drug Discovery. The agreement provides for initial ligand screening of UCB discovery targets. ZoBio will immobilize the targets ...
-
UCB and Biogen Idec's oral VLA-4 antagonist (CDP323) enters phase II development for Multiple Sclerosis
(06/27/2007)
UCB and Biogen Idec announced the initiation of a Phase II study of CDP323 - an oral VLA-4 antagonist - under development for relapsing-remitting multiple sclerosis (MS). The double-blind, randomized Phase II study commenced this week with dosing of ...
Additional information
UCB Pharma S.A.
Brussels, Belgium
Company
|
|
|
|
|
|
Top
